Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tafolecimab (IBI-306), a human IgG2 monoclonal antibody, specifically targets and binds to PCSK-9, thus inhibiting PCSK-9-mediated endocytosis of the LDL receptor. This action enhances the clearance of LDL-C, resulting in a decrease in LDL-C levels. Tafolecimab has potential applications in hypercholesterolemia research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $332 | 2-4 weeks | |
5 mg | $996 | 2-4 weeks | |
10 mg | $1,570 | 2-4 weeks |
Description | Tafolecimab (IBI-306), a human IgG2 monoclonal antibody, specifically targets and binds to PCSK-9, thus inhibiting PCSK-9-mediated endocytosis of the LDL receptor. This action enhances the clearance of LDL-C, resulting in a decrease in LDL-C levels. Tafolecimab has potential applications in hypercholesterolemia research [1]. |
Cas No. | 2225109-03-3 |
Storage | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.